637 related articles for article (PubMed ID: 27449797)
1. Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.
Lener MS; Niciu MJ; Ballard ED; Park M; Park LT; Nugent AC; Zarate CA
Biol Psychiatry; 2017 May; 81(10):886-897. PubMed ID: 27449797
[TBL] [Abstract][Full Text] [Related]
2. Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.
Ren Z; Pribiag H; Jefferson SJ; Shorey M; Fuchs T; Stellwagen D; Luscher B
Biol Psychiatry; 2016 Sep; 80(6):457-468. PubMed ID: 27062563
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial.
Milak MS; Rashid R; Dong Z; Kegeles LS; Grunebaum MF; Ogden RT; Lin X; Mulhern ST; Suckow RF; Cooper TB; Keilp JG; Mao X; Shungu DC; Mann JJ
JAMA Netw Open; 2020 Aug; 3(8):e2013211. PubMed ID: 32785636
[TBL] [Abstract][Full Text] [Related]
4. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.
Pham TH; Gardier AM
Pharmacol Ther; 2019 Jul; 199():58-90. PubMed ID: 30851296
[TBL] [Abstract][Full Text] [Related]
5. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
[TBL] [Abstract][Full Text] [Related]
6. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
7. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
Niciu MJ; Ionescu DF; Richards EM; Zarate CA
J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
[TBL] [Abstract][Full Text] [Related]
8. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.
Milak MS; Proper CJ; Mulhern ST; Parter AL; Kegeles LS; Ogden RT; Mao X; Rodriguez CI; Oquendo MA; Suckow RF; Cooper TB; Keilp JG; Shungu DC; Mann JJ
Mol Psychiatry; 2016 Mar; 21(3):320-7. PubMed ID: 26283639
[TBL] [Abstract][Full Text] [Related]
9. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression.
Salvadore G; van der Veen JW; Zhang Y; Marenco S; Machado-Vieira R; Baumann J; Ibrahim LA; Luckenbaugh DA; Shen J; Drevets WC; Zarate CA
Int J Neuropsychopharmacol; 2012 Sep; 15(8):1063-72. PubMed ID: 22040773
[TBL] [Abstract][Full Text] [Related]
10. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
Abdallah CG; Sanacora G; Duman RS; Krystal JH
Annu Rev Med; 2015; 66():509-23. PubMed ID: 25341010
[TBL] [Abstract][Full Text] [Related]
11. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.
Valentine GW; Mason GF; Gomez R; Fasula M; Watzl J; Pittman B; Krystal JH; Sanacora G
Psychiatry Res; 2011 Feb; 191(2):122-7. PubMed ID: 21232924
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of neuregulin 1-ErbB4 signaling in parvalbumin interneurons in the rat brain may contribute to the antidepressant properties of ketamine.
Wang N; Zhang GF; Liu XY; Sun HL; Wang XM; Qiu LL; Yang C; Yang JJ
J Mol Neurosci; 2014; 54(2):211-8. PubMed ID: 24633675
[TBL] [Abstract][Full Text] [Related]
13. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
Gerhard DM; Wohleb ES; Duman RS
Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424
[TBL] [Abstract][Full Text] [Related]
14. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
Henter ID; Park LT; Zarate CA
CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
[TBL] [Abstract][Full Text] [Related]
15. The mechanistic basis for the rapid antidepressant-like effects of ketamine: From neural circuits to molecular pathways.
Ren L
Prog Neuropsychopharmacol Biol Psychiatry; 2024 Feb; 129():110910. PubMed ID: 38061484
[TBL] [Abstract][Full Text] [Related]
16. 7T
Evans JW; Lally N; An L; Li N; Nugent AC; Banerjee D; Snider SL; Shen J; Roiser JP; Zarate CA
Neuropsychopharmacology; 2018 Aug; 43(9):1908-1914. PubMed ID: 29748628
[TBL] [Abstract][Full Text] [Related]
17. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.
Duman RS; Sanacora G; Krystal JH
Neuron; 2019 Apr; 102(1):75-90. PubMed ID: 30946828
[TBL] [Abstract][Full Text] [Related]
18. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
[TBL] [Abstract][Full Text] [Related]
19. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
Owen RT
Drugs Today (Barc); 2012 Jul; 48(7):469-78. PubMed ID: 22844658
[TBL] [Abstract][Full Text] [Related]
20. [Ketamine: a neuropsychotropic drug with an innovative mechanism of action].
Guilloux JP; Nguyen TML; Gardier AM
Biol Aujourdhui; 2023; 217(3-4):133-144. PubMed ID: 38018940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
